Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. Leukemia 2000 Sep;14(9):1570-6

Date

09/20/2000

Pubmed ID

10995002

DOI

10.1038/sj.leu.2401886

Scopus ID

2-s2.0-0033824201 (requires institutional sign-in at Scopus site)   25 Citations

Abstract

Between May 1987 and January 1991, 1354 patients, 1-21 years old, with standard or poor prognosis B-lineage acute lymphocytic leukemia were treated on the Pediatric Oncology Group Study 8602. One thousand three hundred and twenty-three patients entered remission and 1051 patients were randomized on day 43 to an intensification regimen containing L-asparaginase and intermediate-dose methotrexate (regimen B) or cytarabine and intermediate dose methotrexate (regimen C). After completion of intensification at week 25, all patients received the same maintenance therapy until 3 years from diagnosis. Overall 5-year continuous complete remission (CCR) for regimen B was 72+/-2% (s.e.) and for regimen C, 73+/-2% (P = 0.72 by log-rank analysis). Significant differences between treatments for CCR, testicular, CNS relapses overall or with regard to phenotype (pre-B vs early pre-B), gender, or race were not detected. During intensification, regimen C had significantly more bacterial infections (P = 0.05) and days spent in the hospital (P < 0.001) compared with regimen B, while regimen B had significantly more allergic reactions (P < 0.0001). No significant differences in CCR were noted between patients with pre-B and early pre-B ALL (P = 0.22 stratified by risk group and treatment). This study was unable to detect statistical difference between asparaginase (regimen B) and cytarabine (regimen C) during the intensification phase of therapy in children with B-lineage acute lymphocytic leukemia.

Author List

Harris MB, Shuster JJ, Pullen J, Borowitz MJ, Carroll AJ, Behm FG, Camitta B, Land VJ



MESH terms used to index this publication - Major topics in bold

Adolescent
Adult
Antimetabolites, Antineoplastic
Antineoplastic Combined Chemotherapy Protocols
Asparaginase
Burkitt Lymphoma
Child
Child, Preschool
Cytarabine
Disease-Free Survival
Double-Blind Method
Female
Humans
Infant
Male
Methotrexate
Treatment Outcome